8-K: Viking Therapeutics Announces Positive Clinical Trial Results and Provides Corporate Update

Viking Therapeutics reported positive results from multiple clinical trials and provided a corporate update, including plans to advance VK2735 into Phase 3 development for obesity.

Summary

• Viking Therapeutics announced its second quarter 2024 financial results and provided a corporate update.
• The company reported positive results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, showing up to a 15% reduction in body weight after 13 weeks.
• An oral formulation of VK2735 also showed positive results in a Phase 1 study, with subjects experiencing up to 5.3% weight loss after 28 days.
• Viking plans to advance the subcutaneous VK2735 to Phase 3 and initiate a Phase 2 trial for the oral formulation in the fourth quarter of 2024.
• The Phase 2b VOYAGE study of VK2809 for NASH and fibrosis demonstrated best-in-class histology data, with NASH resolution rates ranging from 63% to 75% and fibrosis improvement rates from 44% to 57%.
• Enrollment is complete for the Phase 1b study of VK0214 for X-ALD, with data expected in the second half of 2024.
• Preclinical data from a novel amylin agonist program showed significant weight loss in animal models, with an IND filing planned for 2025.
• Viking ended the quarter with $942 million in cash, cash equivalents, and short-term investments.
• The company reported a net loss of $22.3 million, or $0.20 per share, for the three months ended June 30, 2024, and a net loss of $49.6 million, or $0.46 per share, for the six months ended June 30, 2024.

Sentiment

Score: 8

Explanation: The document is highly positive due to the strong clinical results, advancement of multiple programs, and a robust cash position. The company is making significant progress in its key therapeutic areas.

Positives

• The Phase 2 VENTURE study of subcutaneous VK2735 demonstrated significant weight loss and good tolerability.
• The oral formulation of VK2735 showed promising weight loss results and a good safety profile.
• VK2809 demonstrated best-in-class efficacy on both NASH resolution and fibrosis improvement.
• The company has a strong cash position of $942 million.
• The novel amylin agonist program showed promising preclinical results.
• The company has multiple programs advancing through clinical trials.

Negatives

• The company reported a net loss of $22.3 million for the quarter and $49.6 million for the six months ended June 30, 2024.
• Research and development expenses increased significantly compared to the same periods in 2023.

Risks

• Clinical trial results may not be replicated in larger studies.
• Regulatory approvals are not guaranteed.
• The company is subject to risks associated with the cost and timing of product development.
• The company is reliant on the success of its clinical programs.
• The company is currently operating at a loss.

Future Outlook

Viking plans to advance VK2735 into Phase 3 development for obesity, initiate a Phase 2 trial for the oral formulation of VK2735, and file an IND for its amylin agonist program in 2025. The company also expects to report data from the Phase 1b study of VK0214 in the second half of 2024.

Management Comments

• The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program, stated Brian Lian, Ph.D., chief executive officer of Viking.

Industry Context

The announcement comes amid growing interest in treatments for obesity and NASH, with several companies developing therapies targeting these conditions. Viking's positive results position them as a strong contender in these competitive markets.

Comparison to Industry Standards

• The 15% weight loss achieved with subcutaneous VK2735 is competitive with other GLP-1 based therapies in development, such as Eli Lilly's Tirzepatide which has shown similar results.
• The NASH resolution rates of 63-75% with VK2809 are considered best-in-class, exceeding results from other companies such as Madrigal Pharmaceuticals with their resmetirom.
• The oral formulation of VK2735 provides a potential advantage over injectable therapies, addressing patient preferences and potentially improving adherence.
• The company's strong cash position of $942 million provides a significant advantage over many smaller biotech companies, allowing them to fund multiple clinical programs.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical results and the company's financial position.
• Employees may be motivated by the progress of the company's pipeline.
• Patients may benefit from the development of new therapies for obesity, NASH, and X-ALD.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Advance VK2735 into Phase 3 development for obesity.
• Initiate a Phase 2 trial for the oral formulation of VK2735 in the fourth quarter of 2024.
• Schedule end-of-Phase 2 meetings with the FDA for VK2735 and VK2809.
• Report data from the Phase 1b study of VK0214 in the second half of 2024.
• File an IND for the novel amylin agonist program in 2025.

Key Dates

Keywords

VK2735, VK2809, VK0214, obesity, NASH, fibrosis, X-ALD, amylin agonist, clinical trials, metabolic disorders, biopharmaceutical